- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07115862
- Original retssag
Effekter af granatæble juice på ulcerøs colitis
Effekt af granatæblejuice på tarmbetændelse, livskvalitet og tarmmikrobiomet hos patienter med ulcerøs colitis: en pilotundersøgelse
The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:
- lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life
- affect the microbes living in the gut (gut microbiota)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
the study is aimed at evaluating the effects of pomegranate juice (PomJ) on: 1) gut inflammation (fecal calprotectin and Simple Clinical Colitis Activity Index) and quality of life; 2) circulating inflammatory markers (e.g., hs-CRP, IL-6, IL-10, TNF-a, IL-1b, IL-8, LBP, LPS) and markers of oxidative stress (blood and urine malondialdehyde (MDA)) and 3) gut microbiota composition and functionality (urinary and circulating urolithin metabolites, fecal SCFAs/BAs, blood LBP and LPS, etc.). We will perform a randomized, controlled, 16-week trial to generate preliminary evidence on the effects of PomJ consumption in patients with mild-to-moderate UC. Participants will be randomly assigned to one of two groups: intervention group and delayed start group. The study will involve 2 phases, each lasting for 8 weeks. During Phase 1, the intervention group will consume 237 ml of PomJ daily, while the delayed start group will follow their habitual diet. Data generated from the delayed start group during Phase 1 will serve as the control for the study. During Phase 2, the intervention group will stop consuming PomJ and switch to consuming their habitual diet, while the delayed start group will consume 237 ml of PomJ daily for 8 weeks. Data generated from the intervention group during Phase 2 will serve as a follow-up to explore whether the effects of PomJ consumption persist after consumption is stopped (this will be an exploratory outcome).
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Tatiana Diacova, PhD, MS, RDN
- Telefonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90073
- Ikke rekrutterer endnu
- West Los Angeles VA Medical Center
-
Ledende efterforsker:
- Zhaoping Li, MD, PhD
-
Kontakt:
- Tatiana Diacova, PhD, MS, RD
- Telefonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- UCLA Center for Human Nutrition
-
Ledende efterforsker:
- Zhaoping Li, MD, PhD
-
Kontakt:
- Tatiana Diacova, PhD, MS, RD
- Telefonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
-
Underforsker:
- Berkeley Limketkai, MD, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
• Adults ≥ 18 yo
- Following a low-polyphenol and fiber diet (< 3 servings of fruits/vegetables per day)
- Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5)
- Supportive evidence of active inflammation (hsCRP >1 mg/L, fecal calprotectin >50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC
- Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening
- Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit
- At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX
- Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.
Exclusion Criteria:
-
• Non-English speaker
- Vegetarian/vegan
- Known pomegranate allergy
- Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass
- Patients with CD, indeterminate/severe to fulminant colitis
- History of colectomy or colonic dysplasia
- Presence of ileal pouch or ostomy
- Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova & parasites, Clostridium difficile, and stool culture
- Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids
- Presence of the following labs indicative of severe colitis: a. Hemoglobin < 8.0 g/dl b. Albumin < 3.0 g/dl
- Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications
- Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration
- Use of Total Parenteral Nutrition (TPN)
- Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening
- Taking exogenous hormones (e.g., hormone replacement therapy)
- Recent weight fluctuations (>10% in the last 6 months)
- Smoker or living with a smoker
- Use of >20 g of alcohol per day
- Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study)
- Unable to provide consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
Participants in this arm will be consuming 237 ml of pomegranate juice for the first 8 weeks of the study and their habitual diet without pomegranate juice for the second 8 weeks |
237 ml of pomegranate juice for the first 8 weeks -> habitual diet for the second 8 weeks |
|
Eksperimentel: Delayed start
Participants in this arm will consume their habitual diet for the first 8 weeks of the study and drink 237 ml of pomegranate juice for the second 8 weeks |
habitual diet for the first 8 weeks -> 237 ml of pomegranate juice for the second 8 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
simple clinical colitis activity index (SCCAI)
Tidsramme: At baseline, 8 weeks and 16 weeks
|
Simple Clinical Colitis Activity Index (SCCAI) includes questions about bowel frequency, urgency of defecation, etc. Measured by the number of points/scores. |
At baseline, 8 weeks and 16 weeks
|
|
Fecal calprotectin
Tidsramme: At baseline, 8 weeks and 16 weeks
|
To evaluate effects of PomJ on gut inflammation in patients with mild-to-moderate UC. The primary outcome will be levels of fecal calprotectin (objective measure). Fecal calprotectin levels will be assessed via a commercially available ELISA kit in mcg/g. |
At baseline, 8 weeks and 16 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, week 8 and week 16
|
Blood interleukin-6 (IL-6) in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, week 8 and week 16
|
Blood interleukin-10 (IL-10) in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of aging and oxidative stress
Tidsramme: At baseline, week 8 and week 16
|
Blood TNF-a in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, week 8 and 16
|
Blood IL-1b in pg/ml |
At baseline, week 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, weeks 8 and 16
|
Blood IL-8 in pg/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At Baseline, weeks 8 and 16
|
Blood hs-CRP in mg/ml |
At Baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, weeks 8 and 16
|
Urine malondialdehyde (MDA) in ng/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, weeks 8 and 16
|
Blood MDA in nmol/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, weeks 8 and 16
|
Urine 8OHdG in ng/mg |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tidsramme: At baseline, weeks 8 and 16
|
Blood 8OHdG in ng/ml |
At baseline, weeks 8 and 16
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gut-derived metabolites
Tidsramme: At baseline, weeks 8 and 16
|
Blood urolithin metabolites in micromoles/L |
At baseline, weeks 8 and 16
|
|
Gut-derived metabolites
Tidsramme: At baseline, weeks 8 and 16
|
Urine urolithin metabolites |
At baseline, weeks 8 and 16
|
|
Microbial inflammatory components
Tidsramme: At baseline, weeks 8 and 16
|
Blood lipopolysaccharide in ng/ml |
At baseline, weeks 8 and 16
|
|
Microbial inflammatory components
Tidsramme: At baseline, weeks 8 and 16
|
Blood LPS binding protein in micrograms/ml |
At baseline, weeks 8 and 16
|
|
Microbial-derived metabolites
Tidsramme: At baseline, weeks 8 and 16
|
Fecal short-chain fatty acids (SCFAs) in micromoles/g |
At baseline, weeks 8 and 16
|
|
Microbial-derived metabolites
Tidsramme: At baseline, weeks 8 and 16
|
Fecal bile acids (BAs) in ng/ml |
At baseline, weeks 8 and 16
|
|
Gut microbiota composition
Tidsramme: At baseline, weeks 8 and 16
|
The stool specimen will be collected by the participants at home at baseline and week 12 utilizing our Stool Collection Kit as per instructions. Immediately after collection, the specimen will be frozen in a home freezer and delivered in an insulated container to the UCLA Center for Human Nutrition. At UCLA, the specimen will be stored at - 80 ºC. Fecal microbiological analyses. Approximately 1g of the stool will be weighed and dried in a vacuum drying oven (15 in Hg) at 80 ºC for 48 hours, then weighed again to establish the moisture content so that all counts can be corrected to dry weight. From another aliquot of remaining fecal samples, DNA will be extracted using bead beating with a commercial extraction system (DNeasy PowerSoil® DNA Isolation Kit, Qiagen, Valencia, CA). The quality of the DNA samples will be confirmed using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE). Extracted DNA will be transferred to UCLA Microbiome Core facility for MiSeq sequencing. |
At baseline, weeks 8 and 16
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Zhaoping Li, MD, PhD, University of California, Los Angeles
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB-25-1553
- T32DK007180 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data analysis will be performed in-house.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .